Stockreport

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's [Seeking Alpha]

Cognition Therapeutics, Inc.  (CGTX) 
PDF CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aß oligomers. Preliminary data fr [Read more]